Ibtrozi (taletrectinib) is approved for ROS1-positive NSCLC, showing high efficacy in TRUST-I and TRUST-II trials. Treatment-naive patients had response rates of 90% and 85%, with significant duration ...
Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...
Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC, outperforming current market leaders in key metrics like DOR and PFS. Despite a small target market, ...
While three Big Pharma companies have yet to successfully crack the ROS1 lung cancer market, young biotech Nuvalent believes competitive pivotal data from its investigational drug are paving the way ...
NEW YORK & SEOUL, South Korea--(BUSINESS WIRE)--AnHeart Therapeutics and NewG Lab Therapeutics, a subsidiary of NewG Lab Pharma, announced that the Ministry of Food and Drug Safety (MFDS), Republic of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback